Browse VCAN

Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix.
Domain PF00008 EGF-like domain
PF00059 Lectin C-type domain
PF00084 Sushi repeat (SCR repeat)
PF07686 Immunoglobulin V-set domain
PF00193 Extracellular link domain
Function

May play a role in intercellular signaling and in connecting cells with the extracellular matrix. May take part in the regulation of cell motility, growth and differentiation. Binds hyaluronic acid.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006029 proteoglycan metabolic process
GO:0006790 sulfur compound metabolic process
GO:0008037 cell recognition
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0030166 proteoglycan biosynthetic process
GO:0030198 extracellular matrix organization
GO:0030203 glycosaminoglycan metabolic process
GO:0030204 chondroitin sulfate metabolic process
GO:0030205 dermatan sulfate metabolic process
GO:0030206 chondroitin sulfate biosynthetic process
GO:0030207 chondroitin sulfate catabolic process
GO:0030208 dermatan sulfate biosynthetic process
GO:0043062 extracellular structure organization
GO:0044272 sulfur compound biosynthetic process
GO:0044273 sulfur compound catabolic process
GO:0050650 chondroitin sulfate proteoglycan biosynthetic process
GO:0050651 dermatan sulfate proteoglycan biosynthetic process
GO:0050654 chondroitin sulfate proteoglycan metabolic process
GO:0050655 dermatan sulfate proteoglycan metabolic process
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1903510 mucopolysaccharide metabolic process
Molecular Function GO:0005201 extracellular matrix structural constituent
GO:0005539 glycosaminoglycan binding
GO:0005540 hyaluronic acid binding
GO:0030246 carbohydrate binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0043202 lysosomal lumen
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis
R-HSA-2024101: CS/DS degradation
R-HSA-2022870: Chondroitin sulfate biosynthesis
R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-3560801: Defective B3GAT3 causes JDSSDHD
R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type
R-HSA-3595174: Defective CHST14 causes EDS, musculocontractural type
R-HSA-3595172: Defective CHST3 causes SEDCJD
R-HSA-3595177: Defective CHSY1 causes TPBS
R-HSA-2022923: Dermatan sulfate biosynthesis
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between VCAN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of VCAN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of VCAN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.780.00894
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.180.331
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.4790.354
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3780.485
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7770.793
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1370.973
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2880.673
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2090.919
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3890.865
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7390.75
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8840.557
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2840.19
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of VCAN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.115.1-40.753
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.116.9-5.80.747
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.83.712.10.224
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.27.710.50.63
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.5012.50.485
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VCAN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VCAN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VCAN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VCAN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of VCAN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between VCAN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolVCAN
Nameversican
Aliases PG-M; versican proteoglycan; CSPG2; chondroitin sulfate proteoglycan 2; GHAP; WGN; WGN1; chondroitin sulfate ......
Chromosomal Location5q14.2-q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting VCAN collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting VCAN.
ID Name Drug Type Targets #Targets
DB08818Hyaluronic acidSmall MoleculeC1QBP, CD44, HABP2, HABP4, HAPLN1, HAPLN3, HAPLN4, HMMR, ICAM1, IM ......15